United States v. Stepanets

879 F.3d 367
CourtCourt of Appeals for the First Circuit
DecidedJanuary 12, 2018
Docket16-2402P
StatusPublished
Cited by13 cases

This text of 879 F.3d 367 (United States v. Stepanets) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Stepanets, 879 F.3d 367 (1st Cir. 2018).

Opinion

THOMPSON, Circuit Judge.

Preface

The government appeals from orders dismissing counts in an indictment that charged Alla Stepanets, Kathy Chin, and Michelle Thomas with “dispensing]” mis-branded drugs in violation of the Federal Food, Drug, and Cosmetic Act, see 21 U.S.C. §§ 353(b)(1), 331(a), and 333(a)(2)— a statute that often goes by the unpronounceable initialism “FFDCA.” Reviewing the matter de novo, see United States v. Guerrier, 669 F.3d 1, 3 (1st Cir. 2011), we think dismissal was not called for. And so we reverse and remand for further proceedings.

FFDCA Primer

Here is what you need to know about the FFDCA (we simplify a bit). Enacted many decades ago “to protect consumers from dangerous products,” see United States v. Sullivan, 332 U.S. 689, 696, 68 S.Ct. 331, 92 L.Ed. 297 (1948), the FFDCA bans “[t]he introduction or delivery for introduction into interstate commerce of any ... misbranded” prescription drug, see 21 U.S.C. § 331(a). A prescription drug is “misbranded” if it is “dispensed” without “a written prescription of a practitioner licensed by law to administer such drug.” Id. § 353(b)(1). “Dispensed” is an undefined FFDCA term, however. Anyhow, anyone who violates this law “with the intent to defraud or mislead” commits a crime punishable with up to three years in prison. See id. § 333(a)(2).

Case Background

Shifting from the general to the specific, we believe a simple sketch of the key events suffices to put things in perspective. A quick heads up, though: because the judge dismissed the charges before trial, we describe the facts as though the government had proved what the indictment alleged, see United States v. Councilman, 418 F.3d 67, 71-72 (1st Cir. 2005) (en banc)—which of course is not the case.

The Defendants

Stepanets, Chin, and Thomas were Massachusetts-licensed pharmacists. That meant they could (among other things) dispense drugs, but only through “valid prescriptions from a medical practitioner.” 1 The trio worked as pharmacists for New England Compounding Center (“NECC” for short), a now-defunct Massachusetts-licensed pharmacy that specialized in “high-risk compounding”—a process that involves “using non-sterile ingredients to create sterile drugs.” Assigned to NECC’s “packing area,” they “check[ed]” drug “orders” before “shipment to NECC’s customers.”

The Indictment

' Eventually, Stepanets, Chin, and Thomas got swept up in a 131-count indictment that included 11 other persons with NECC ties. The gargantuan document catalogs an array of felonious conduct—for example, it alleges that NECC failed to follow proper sterilization procedures, opted to use expired or expiring ingredients, arid neglected to run proper tests. As relevant for our purposes, the indictment alleges that our defendants dispensed drugs in violation of the FFDCA, specifically by causing mis-branded drugs to be introduced into interstate commerce with the intent to defraud or mislead. And the indictment charges them both as principals and as aiders and abettors, gee 18 U.S.C. § 2 (making aiders and abettors punishable as principals for the offenses they aided and abetted).

The indictment is quite detailed—as a for-instance, the indictment identifies particular drug shipments to particular places on particular dates based on prescriptions for fake patients, and it specifies the laws the defendants allegedly broke. By way of illustration, just consider the following allegations pulled from the indictrrient:

• on February 18, 2010, Stepanets caused 60 vials of “betamethasone repository’ to be delivered to Lincoln, Nebraska, based on prescriptions for “Wonder Woman” and “Fat Albert,” among others; 2
• similarly, on March 8, 2012, Chin caused 60 vials of “betamethasone repository” to. be delivered to Lincoln, Nebraska, based on prescriptions for “Flash Gordon,” “Tony'Tiger,” and “Chester Cheeto,” among others;
• and on March 20, 2012, Thomas and Stepanets caused 12 vials of “be- . tamethasone repository” to be deliv-rired to Elkhart, Indiana, based on prescriptions for “L.L. Bean,” “Coco Puff,” and “Filet O’fish,” among others. 3 ,

Also, the indictment notes the statutory bases for the charges—21 U.S.C. §§ 353(b)(1), 331(a), and 333(a)(2), and 18 U.S.C. § 2—and mimics their language in key respects.

, The Dismissal Battles

Responding to the indictment, Stepan-ets, Chin, and Thomas moved to dismiss the FFDCA charges against them—Step-anets filed her own motion, and Chin and Thomas filed a joint motion. Stepanets argued that she was not sufficiently involved in NECC’s process to have “dispensed” the drugs and that the pertinent FFDCA provisions are' unconstitutionally vague as applied to her. Chin and Thomas argued that the FFDCA does not require prescriptions to be “valid” for licensed' pharmacists to fill them; " that as a factual matter they were not personally responsible for taking the steps they deemed necessary for them to have “dispensed” the drugs; and that the parts of the FFDCA covering their conduct are impermissibly vague as applied to them. The government responded that the FFDCA does not allow licensed pharmacists to fill obviously fraudulent prescriptions; that the indictment’s allegations—which must be taken as true—support the charges; and that the FFDCA is sufficiently clear to withstand the defendants’ vagueness challenges.

Acting on the parties’ submissions, the judge dismissed the FFDCA counts against the defendants. Stripped to essentials, the judge’s reasoning went something like this: The indictment’s allegations, the judge wrote, show that the defendants “knew or should have known that at least some of the shipping labels were made out in the names of fictitious patients.” But, the judge added, that conclusion helped the government only so much.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Coleman
First Circuit, 2025
United States v. Reyes-Valdivia
84 F.4th 400 (First Circuit, 2023)
United States v. Thomas
15 F.4th 536 (First Circuit, 2021)
United States of America v. P Nathan Craigue
2021 DNH 082 (D. New Hampshire, 2021)
United States of America v. Joseph A. Foistner
2021 DNH 050 (D. New Hampshire, 2021)
United States v. Svirskiy
989 F.3d 88 (First Circuit, 2021)
United States of America v. Laveneur Jackson
2020 DNH 177 (D. New Hampshire, 2020)
United States v. Nathan Craigue
2020 DNH 031 (D. New Hampshire, 2020)
United States v. Vega-Martinez
949 F.3d 43 (First Circuit, 2020)
United States v. Conigliaro
384 F. Supp. 3d 145 (District of Columbia, 2019)
United States v. Rodriguez-Rivera
918 F.3d 32 (First Circuit, 2019)
United States v. Stepanets
362 F. Supp. 3d 22 (District of Columbia, 2019)
US v. Musso
2018 DNH 049 (D. New Hampshire, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
879 F.3d 367, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-stepanets-ca1-2018.